Data completeness
0/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pitressin Tannate (vasopressin tannate) is an injectable formulation of vasopressin, a posterior pituitary hormone analog used to treat diabetes insipidus and variceal bleeding. The drug works by mimicking the natural antidiuretic hormone (ADH), promoting water reabsorption in the kidneys and causing vasoconstriction in splanchnic vasculature. It is a pre-launch product from Pfizer with significant legacy heritage in the vasopressin class.
PRE_LAUNCH
As a pre-launch product, this represents a specialized commercial opportunity with limited market size but potentially high-touch specialty sales and medical affairs engagement.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Pitressin Tannate offers exposure to specialty pharmaceutical launch dynamics and niche endocrine/emergency medicine markets. The pre-launch stage demands cross-functional collaboration, narrow targeting, and deep clinical education—ideal for professionals seeking focused, high-impact roles outside mainstream commercial scale.
Brand ManagerMedical Science Liaison
Worked on PITRESSIN TANNATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.